Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

gulate activation of NF-kB by binding to IKKB, the kinase that inhibits NF-kB activation. The triterpenoids block the activation of STAT3 and STAT5 in cancer cells by upregulating negative regulators of the STATs. These transcription factors are the target of major drug development programs at multiple companies with applications in treating both inflammation and cancer.

-- A description of the anti-inflammatory and anti-carcinogenic activity of the compounds. Reata's triterpenoids suppress production of pro-inflammatory cytokines and reduce mortality in animal models of LPS-induced inflammation. Synthetic triterpenoids are highly effective in preventing the development of both lung cancer and liver cancer in animals exposed to known carcinogens.

-- Multi-functional anti-cancer activity of these drugs, which includes driving immature cancerous cells to differentiate; inhibiting the growth of cancer cells and causing them to undergo programmed cell death (called apoptosis). This activity has been seen in multiple animal models, and has recently been confirmed in a Phase 1 study of RTA 402 in cancer patients being conducted at the M.D. Anderson Cancer Center and the Dana-Farber Cancer Institute.

-- A comparison of the mechanism of the Synthetic Triterpenoids with that of "targeted therapies" currently in vogue in the cancer field. Dr. Sporn argues that the genetic complexity of cancer requires the use of agents with a multi-factorial mode of action, rather than those with high affinity for a single, specific molecular receptor. While multi-factorial mechanisms are often thought to be associated with high drug toxicity, Dr. Sporn notes that these agents are derived from natural products that have been safely used for centuries with no appreciable toxicities. Recent clinical studies have shown that these agents are minimally toxic in humans.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:4/16/2015)... 2015 A drug commonly taken to prevent seizures ... multiple sclerosis (MS), according to a study released today that ... Annual Meeting in Washington, DC , April ... people with MS experience at some point in their life ... carrying vision from the eye to the brain gets inflamed," ...
(Date:4/16/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Tuesday, April 21, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Diplomat Names Shannon M. Beltrand as New CISO 2
... TEMECULA, Calif., Nov. 17 Patient Safety Technologies, Inc. ... results. , "We are continuing to see strong year ... margins," stated Steven H. Kane, Chief Executive Officer of ... sales of safety sponges were comparable with revenues in ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Research Small and Mid Cap Conference on Friday, November 20, 2009 ... general public are invited to listen to a live audio broadcast ... accessed at www.wbmd.com (in the Investor Relations ...
Cached Medicine Technology:Patient Safety Technologies Reports Third Quarter Results 2Patient Safety Technologies Reports Third Quarter Results 3Patient Safety Technologies Reports Third Quarter Results 4Patient Safety Technologies Reports Third Quarter Results 5Patient Safety Technologies Reports Third Quarter Results 6
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. ... of platelet-rich plasma (PRP) and stem cell ... known for its world-class care of injury-caused and chronic ... lacking in many other physicians offering regenerative medicines. ... for pain management and rehabilitation. Dr. Meier and MOSM ...
(Date:4/17/2015)... Tallahassee, Fla. (PRWEB) April 17, 2015 ... percent of dental restoration units are made overseas by ... Commission. Additionally, domestic labs remain unregulated in more than ... , The National Association of Dental Laboratories ... campaign to raise awareness among patients about the consequences ...
(Date:4/17/2015)... Jacksonville, Fla. (PRWEB) April 17, 2015 ... Cancer Center have signed a partnership agreement designed to ... , The institutions have agreed to create a ... Anderson’s treatment protocols and translational research. Baptist MD Anderson ... of 2015, providing a single destination for highly coordinated, ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... Fat Pad Restoration on The Balancing Act on Lifetime TelevisionBOCA ... great doing it" is more than a tag line for ... is a leading expert and innovator in the science of ... a woman, she understands the emotional needs that many women ...
... Pharmakon introduced next generation of health ... quality natural liquid calcium & mineral supplement ... segments of athletes, women in pre and ... calcium supplementation. The innovative products of Aim ...
... the HR outsourcing marketplace, Empyrean Benefit Solutions is changing the status ... lower price. , ... Houston, TX (PRWEB) January 12, ... to grow by over 800% in annual revenue in their first ...
... employ comparative effectiveness research tools to address large, unwarranted variations ... benefits corporate spending. , ... Phoenixville, ... effectiveness data addresses large and unwarranted variations in corporate spending. ...
... SAN FRANCISCO, Jan. 12 Hiemstra Product Development, ... the debut of,hiQual, its proprietary electronic quality management ... the integration of hiQual, Hiemstra,s development team can ... the necessary documentation,required under ISO 13485:2003 and FDA ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
Cached Medicine News:Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 2Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development 2Health News:Acclarent, Inc. Closes $26 Million Financing 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The Vibratome Roto-Shake Genie is an ... It performs five different mixing ... and rotating/rolling, as well as a ... The precision-engineered moving portion of the ...
... The Vibratome Roto-Shake Genie is ... platform. It performs five different ... rolling/rocking and rotating/rolling, as well as ... The precision-engineered moving portion of ...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: